FY2026 Earnings Estimate for ASMB Issued By HC Wainwright

Assembly Biosciences, Inc. (NASDAQ:ASMB – Free Report) – Stock analysts at HC Wainwright cut their FY2026 earnings estimates for Assembly Biosciences in a research note issued to investors on Tuesday, November 17th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings of $1.36 per share for the year, down from their prior forecast of $2.28. HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is $2.28 per share. HC Wainwright also issued estimates for Assembly Biosciences’ Q4 2026 earnings at $2.75 EPS, Q1 2027 earnings at ($0.25) EPS, Q2 2027 earnings at ($0.98) EPS, Q3 2027 earnings at ($0.96) EPS, Q4 2027 earnings at $1.43 EPS, FY2027 earnings at ($0.71) EPS, FY2028 earnings at $0.49 EPS, FY2029 earnings at ($2.21) EPS and FY2030 earnings at $3.07 EPS.

Several other equities analysts have also recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Thursday, October 15th. Mizuho set a $53.00 target price on Assembly Biosciences in a report on Tuesday, September 1st. Zacks Research cut Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 9th. Finally, UBS Group reduced their price target on Assembly Biosciences from $52.00 to $48.00 and set a “buy” rating for the company in a research report on Tuesday, November 3rd. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $46.50.

Get Our Latest Stock Report on ASMB

Assembly Biosciences Price Performance

Assembly Biosciences stock opened at $22.39 on Thursday. The firm has a 50-day moving average of $22.48 and a 200-day moving average of $26.78. Assembly Biosciences has a one year low of $19.20 and a one year high of $39.71. The company has a market cap of $458.55 million, a price-to-earnings ratio of 27.64 and a beta of 1.26.

Assembly Biosciences (NASDAQ:ASMB – Get Free Report) last announced its earnings results on Thursday, November 12th. The biopharmaceutical company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.27). The business had revenue of $2.96 million for the quarter, compared to analyst estimates of $9.07 million. Assembly Biosciences had a negative return on equity of 4.40% and a negative net margin of 16.57%.

Institutional Trading of Assembly Biosciences

Hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC boosted its stake in shares of Assembly Biosciences by 1.4% during the 1st quarter. Janus Henderson Group PLC now owns 849,309 shares of the biopharmaceutical company’s stock worth $23,479,000 after acquiring an additional 11,384 shares during the period. State Street Corp increased its holdings in shares of Assembly Biosciences by 62.7% during the 3rd quarter. State Street Corp now owns 559,590 shares of the biopharmaceutical company’s stock worth $13,145,000 after acquiring an additional 215,728 shares during the last quarter. Seven Fleet Capital Management LP raised its stake in Assembly Biosciences by 671.5% in the 2nd quarter. Seven Fleet Capital Management LP now owns 433,147 shares of the biopharmaceutical company’s stock valued at $11,903,000 after acquiring an additional 377,000 shares during the period. Stempoint Capital LP lifted its holdings in Assembly Biosciences by 18.3% during the 1st quarter. Stempoint Capital LP now owns 185,435 shares of the biopharmaceutical company’s stock valued at $5,146,000 after purchasing an additional 28,707 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in Assembly Biosciences by 39.1% during the 3rd quarter. Goldman Sachs Group Inc. now owns 191,747 shares of the biopharmaceutical company’s stock valued at $4,504,000 after purchasing an additional 53,914 shares during the last quarter. 19.92% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Assembly Biosciences

In other news, insider Nicole White sold 2,593 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $19.62, for a total value of $50,874.66. Following the sale, the insider directly owned 59,257 shares of the company’s stock, valued at approximately $1,162,622.34. This represents a 4.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jason Okazaki sold 6,202 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $19.62, for a total transaction of $121,683.24. Following the completion of the sale, the chief executive officer owned 195,532 shares of the company’s stock, valued at $3,836,337.84. This trade represents a 3.07% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 12,115 shares of company stock worth $237,696 in the last ninety days. Insiders own 3.50% of the company’s stock.

Key Assembly Biosciences News

These are some of the ASMB news items that stood out recently:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and $50 price target, offering a bullish counterpoint to its reduced forecasts. MarketBeat ASMB coverage
  • Neutral Sentiment: Assembly Biosciences appeared at the UBS Global Biopharma Conference; the provided transcript listing does not include specific new company updates. UBS conference transcript
  • Negative Sentiment: HC Wainwright cut its FY2026 EPS estimate to $1.36 from $2.28 and its FY2027 forecast to a loss of $0.71 per share from earnings of $0.05. It also reduced estimates for FY2028 ($0.49 from $0.84), Q4 2026 ($2.75 from $3.19), and multiple 2027 quarters—including changing Q1 from a $0.02 profit to a $0.25 loss. These broad downward revisions may weigh on investor expectations, despite a slight improvement in its FY2029 loss estimate. MarketBeat ASMB coverage

About Assembly Biosciences

(Get Free Report)

Assembly Biosciences is a clinical-stage biotechnology company focused on developing oral antiviral therapies for viral infections. Its research programs target hepatitis B virus (HBV) and herpesviruses, including herpes simplex virus. The company’s pipeline includes investigational antiviral candidates designed to interfere with key steps in viral replication. Assembly has also worked with Gilead Sciences on antiviral development, including programs targeting herpesviruses. Its therapies remain under investigation and are not approved medicines.

Further Reading

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.